Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

YAP/TAZ Binds to Selected Superenhancers and Controls Pol II Pause Release

DOI: 10.1158/2159-8290.CD-RW2015-194 Published December 2015
  • Article
  • Info & Metrics
Loading
  • Major finding: YAP occupies a subset of highly active enhancers and regulates RNA Pol II pause release.

  • Mechanism: YAP recruits the mediator complex and CDK9 to chromatin, promoting YAP target gene transcription.

  • Impact: YAP binds to selected enhancers associated with critical growth genes important for tumorigenesis.

The Hippo pathway is an important regulator of cell growth and stem cell activity. When Hippo signaling is inactive, the transcriptional coactivator YAP and its paralogue TAZ translocate to the nucleus, where they bind TEAD transcription factors and regulate genes that result in increased organ size and tumorigenesis. Despite the importance of this pathway in cancer, the factors recruited by YAP/TAZ and TEADs and the binding sites of YAP/TAZ on chromatin remain largely unknown. Galli and colleagues used chromatin immunoprecipitation sequencing (ChIP-seq) in liver cancer cells to analyze the genome-wide occupancy of YAP, TEAD1, TEAD4, and TAZ, which revealed that YAP and TAZ have redundant occupancy patterns at a small subset of TEAD-bound distal regulatory enhancer elements. The YAP-bound enhancers were highly active with a higher density of activating histone marks than the average enhancer and high expression of the associated target genes. Twenty-five percent of the YAP-bound enhancers were classified as superenhancers (compared with only 2% of YAP-negative enhancers), and represent 17% of all superenhancers in the cell. YAP/TAZ was essential for the transcriptional output of these enhancers, with YAP/TAZ knockdown leading to loss of expression of the associated genes. YAP increased the transcriptional rate through the reduction of RNA polymerase II (Pol II) pausing, thereby enhancing transcriptional elongation. Mechanistically, YAP recruited the Mediator complex to target sites, allowing for the recruitment of the elongating kinase cyclin-dependent kinase 9 (CDK9), which controls transcriptional pause release and increases transcriptional activity. Silencing of Mediator or inhibition of CDK9 diminished YAP target gene expression and decreased YAP-driven growth and tumorigenesis. Taken together, these findings define the role of YAP at active distal enhancer regions in promoting RNA Pol II pause release and transcriptional elongation. These results may have clinical implications in YAP-driven tumors, which may benefit from transcriptional elongation inhibitors.

Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B, et al. YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol Cell 2015 Oct 1 [Epub ahead of print].

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
YAP/TAZ Binds to Selected Superenhancers and Controls Pol II Pause Release
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
YAP/TAZ Binds to Selected Superenhancers and Controls Pol II Pause Release
Cancer Discov December 1 2015 (5) (12) OF21; DOI: 10.1158/2159-8290.CD-RW2015-194

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
YAP/TAZ Binds to Selected Superenhancers and Controls Pol II Pause Release
Cancer Discov December 1 2015 (5) (12) OF21; DOI: 10.1158/2159-8290.CD-RW2015-194
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Transcriptional Regulation

  • BET Degradation Is More Effective Than Competitive Inhibition in T-ALL
  • The RagD GTPase Regulates mTORC1 Activity to Promote Tumor Growth
  • Epigenetic Drugs Promote Transcription from Cryptic Start Sites
Show more Transcriptional Regulation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement